<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15115">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910102</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-101-2003</org_study_id>
    <nct_id>NCT02910102</nct_id>
  </id_info>
  <brief_title>Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axovant Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axovant Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in
      patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease
      Dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative
      gait and balance parameters.

      Each subject will be randomized 1:1 to one of the following sequences:

      Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late
      treatment period

      Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late
      treatment period

      Treatment A = RVT-101 35 mg once daily.

      Treatment B = Placebo once daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative gait measurements from baseline to the end of each double-blind treatment period based on computerized gait assessment tools.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, and reported changes in physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments from baseline to the end of each double-blind treatment period.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Parkinson's Disease Dementia</condition>
  <arm_group>
    <arm_group_label>RVT-101 35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVT-101 35 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-101 35 mg</intervention_name>
    <description>once daily, oral, 35-mg tablets</description>
    <arm_group_label>RVT-101 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily, oral, matching tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female subject with a clinical diagnosis of Alzheimer's disease (AD),
             dementia with Lewy bodies (DLB), or Parkinson's disease dementia (PDD).

          2. Mini Mental State Examination score 14 to 26

          3. Gait impairment, as assessed by history gathered by the clinical investigator and
             quantitative measurements

          4. Subjects must be on stable background acetylcholinesterase inhibitor therapy

        Key Exclusion Criteria:

          1. History and/or evidence of any other CNS disorder that could be interpreted as a
             cause of dementia (in the opinion of the investigator)

          2. Any clinically relevant concomitant disease which, in the opinion of the
             investigator, makes the subject unsuitable for inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilise Lombardo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Axovant Sciences, Inc., Senior VP Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axovant Clinical Trials</last_name>
    <phone>646-677-6770</phone>
  </overall_contact>
  <location>
    <facility>
      <name>US101</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US103</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US102</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://axovant.com/pipeline/intepirdine-rvt-101/mechanism-of-action/</url>
    <description>Click here for more information about intepirdine (RVT-101)</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 20, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RVT-101</keyword>
  <keyword>intepirdine</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Lewy body dementia</keyword>
  <keyword>Parkinson's Disease Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
